What is the revenue and EPS growth rate for Molina Healthcare year over year?

What guidance did Molina Healthcare's management provide for the next earnings period?

What were the key takeaways from Molina Healthcare's earnings call?

What is the market's earnings forecast for Molina Healthcare next quarter?

What is Molina Healthcare's latest dividend and current dividend yield?

What were the key takeaways from Molina Healthcare’s earnings call?

What is Molina Healthcare's gross profit margin?

What does Molina Healthcare do and what are its main business segments?

- **2025 Performance**: Full-year EPS of $11.03 vs. $24.50 guidance due to 7.5% medical cost trend and Marketplace volatility.
- **2026 Outlook**: EPS guidance of $5 (underlying $7.50) reflects Florida CMS contract drag ($1.50) and MAPD exit ($1). Medicaid MCR 92.9% (1.2% margin), Medicare MCR 94% (negative 1.7%).
- **Growth Drivers**: $6B Florida CMS contract (Q4 2026 incept) and $50B RFP pipeline. Embedded earnings exceed $11 per share.
- **Risk Management**: 2% organic Medicaid attrition in 2026, reduced Marketplace exposure by 50%, and 70% renewal rate in ACA.
- **Long-Term Vision**: 2026 is Medicaid margin trough (1.2%), with potential for 300-400bps rate restoration and return to target margins by 2028.

**【CEO Summary Section】**
- **Q4 2025 Results**: Adjusted loss of $2.75 per share due to Medicaid retroactive items ($2 per share) and elevated utilization in Medicare and Marketplace. Full-year 2025 EPS was $11.03, below guidance due to 7.5% medical cost trend (vs. 4.5% initial estimate) and Marketplace volatility.
- **2026 Guidance**: Projected EPS of at least $5, with $1.50 drag from Florida CMS contract and $1 from MAPD exit. Underlying EPS of $7.50 assumes 4% Medicaid rates and 5% trend. Upside risks include trend moderation, rate adjustments, and Medicare/Marketplace performance.
- **Growth Initiatives**: Secured $6B Florida CMS contract (incepting Q4 2026) and renewed Wisconsin LTSS contract. $50B pipeline of new RFPs and active M&A pipeline for Medicaid accretion.
- **Long-Term Outlook**: 2026 is Medicaid margin trough (1.2% pretax), with potential for 300-400bps rate restoration. Embedded earnings exceed $11 per share, driven by new contracts and rate cycle recovery.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: $10.7B premium revenue, 93.5% Medicaid MCR (2% pretax margin ex retro items). Medicare MCR 97.5%, Marketplace MCR 99% due to behavioral health and drug trends.
- **2026 Financials**: $42B premium revenue (flat vs 2025), 0.8% pretax margin. Medicaid MCR 92.9% (1.2% margin), Medicare MCR 94% (negative 1.7%), Marketplace MCR 85.5% (1.7% margin). G&A ratio 6.4%, effective tax rate 30%.
- **Balance Sheet**: $223M parent company cash, 3.7x debt/EBITDA. Operating cash flow outflow of $535M in 2025 due to risk corridor settlements.

**【Q&A Highlights】**
- **Medicaid Margin Variance**: States underfunded by 300-400bps, but Molina maintains 2%+ pretax margin despite 7.5% trend. Florida CMS contract expected to reach target margins by 2028.
- **California Retro Items**: $135M impact from undocumented population corridor and LA County risk adjustment. Unlikely to recur in 2026.
- **Attrition Assumptions**: 2% organic Medicaid attrition in 2026 (vs. 4% in 2025), driven by reduced low/no users (5% decline in cohort).
- **Marketplace Strategy**: Reduced exposure by 50% to stabilize margins, with 70% renewals and 30% new members. Effectuation rate ~60%.
- **M&A Strategy**: Actively pursuing single-state payers in underpenetrated markets, targeting 20%+ revenue multiples for accretive acquisitions.

Molina Healthcare, Inc. (MOH) Q4 2025 Earnings Call Transcript

- **EPS Downgrade**: 2025 EPS revised to $14 (from $19), with Marketplace underperformance (50% of reduction) and Medicaid rate/trend imbalance as key drivers.
- **Marketplace Restructuring**: 2026 rate increases of 15-45%, reduced footprint by 20%, targeting breakeven on $1.5-$2B revenue.
- **Medicaid Margin Outlook**: 2026 baseline MCR of 91.3%, with potential upside from 100bps rate catch-up ($4.50 EPS) and $8.65 embedded earnings pipeline.
- **Balance Sheet Strength**: Parent company cash of $108M, RBC ratios at 340%, and debt-to-EBITDA of 2.5x support growth initiatives.
- **Growth Catalysts**: Georgia/Texas Medicaid wins, Medicare duals expansion, and $54B M&A pipeline targeting low-margin, book-value acquisitions.

**【CEO Summary Section】**
- **Q3 2025 Performance**: Adjusted EPS of $1.84, consolidated MCR of 92.6%, and premium revenue of $10.8 billion. Medicaid MCR of 92%, Medicare MCR of 93.6%, and Marketplace MCR of 95.6% reflect elevated medical cost trends across segments.
- **2025 Guidance Update**: Full year EPS revised to $14 (down from $19), driven by Marketplace underperformance (50% of EPS reduction) and Medicaid rate/trend imbalance. Full year MCR expected at 91.3%.
- **2026 Outlook**: Baseline EPS similar to 2025 guidance ($14), with potential upside from Medicaid rate catch-up (100bps of MCR yields $4.50 EPS) and embedded earnings ($8.65 per share pipeline). Marketplace revenue expected to decline to $1.5-$2 billion but targeted for breakeven margins.
- **Growth Initiatives**: $46 billion 2026 revenue target includes Georgia/Texas Medicaid wins, Medicare duals growth, and M&A pipeline of $54 billion opportunities. Share repurchases ($500M in Q3) reflect confidence in long-term margin targets despite short-term challenges.

**【CFO Financial Commentary】**
- **Q3 Financials**: GAAP net income of $278M, adjusted G&A ratio of 6.3%, and operating cash flow outflow of $237M due to risk corridor settlements. Parent company cash balance of $108M, RBC ratios at 340%, and debt-to-EBITDA of 2.5x.
- **2025 Guidance**: Full year premium revenue of $42.5B, MCR of 91.3%, and EPS of $14. Medicaid pretax margin of 3.2%, Medicare breakeven, and Marketplace negative pretax margin.
- **Capital Allocation**: Prioritized organic growth (Medicaid expansion, Medicare duals) over M&A, with disciplined approach to Marketplace exposure. 2026 G&A ratio expected to rise to 6.8% due to normalized compensation costs.

**【Q&A Highlights】**
- **Marketplace Strategy**: 2026 rate increases of 15-45% (30% average), reduced footprint by 20%, and exit from 50% of top-tier price positions to stabilize risk pool. Target mid-single-digit pretax margins on reduced revenue.
- **Medicaid Rates**: States 300-400bps underfunded, early 2026 rate cycle suggests modest catch-up (50bps above trend). LTSS, pharmacy, and behavioral health trends visible in rating cells support rate adequacy.
- **Embedded Earnings**: $8.65 per share pipeline includes $1 of implementation cost reversal and $0.40 Virginia contract loss. Partial realization in 2026 will depend on trend/rate alignment.
- **Medicare Performance**: MAPD margin improvement offset by FIDE/HIDE conversions. Bright ConnectiCare (MAPD) expected to reach target margins in 2026.
- **M&A Pipeline**: Full $54B pipeline with focus on low-margin, book-value acquisitions in struggling local plans. No plans to exit profitable Medicaid contracts despite industry-wide margin challenges.


Molina Healthcare, Inc. (MOH) Q3 2025 Earnings Call Transcript

- **Q2 Results**: Adjusted EPS $5.48, MCR 90.4%, pretax margin 3.3%. Medicaid MCR 91.3%, Marketplace MCR 85.4%.
- **2025 Guidance**: EPS floor $19 (down $5.50), MCR 90.2%, 140bps increase vs. prior guidance.
- **Segment Trends**: Medicaid trend 6%, Marketplace MCR 85% (83% normalized). Medicare MCR 90%.
- **Growth Targets**: 2026 premium $46B, 2027 $52B. Embedded earnings $8.65, $1 from reversing costs.
- **Marketplace Risk**: 30% enrollment decline in 2026, 10% of revenue kept stable.
- **Budget Bill Impact**: 15-20% expansion population reduction, gradual implementation.

**【CEO Summary Section】**
- **Q2 Financials**: Adjusted EPS of $5.48 on $10.9B premium revenue. Consolidated MCR of 90.4%, with Medicaid MCR at 91.3% and Marketplace MCR at 85.4%. Adjusted pretax margin of 3.3%.
- **Medical Cost Pressures**: Behavioral health, high-cost drugs, inpatient/outpatient utilization driving trend. Medicaid MCR 200-300bps below market average, but rate updates insufficient to offset trend.
- **2025 Guidance Update**: Full-year EPS floor of $19 (down $5.50 from initial $24.50). Consolidated MCR of 90.2%, with 140bps increase vs. prior guidance, 50% attributed to Marketplace.
- **Growth Initiatives**: 2026 premium target of $46B (9% YoY growth), 2027 target of $52B. Embedded earnings of $8.65 per share, with $1 from reversing implementation costs in 2026.
- **Budget Bill Impact**: 15-20% potential reduction in expansion population, gradual implementation expected. Marketplace enrollment decline of ~30% in 2026 due to subsidy expiration.

**【CFO Financial Commentary】**
- **Segment Performance**: 
  - **Medicaid**: Full-year MCR guidance of 90.9% (up 100bps), trend assumption increased to 6% from 5%. 55% of revenue renews in 2026, rate cycle well-timed.
  - **Medicare**: Full-year MCR of 90%, driven by dual eligibles and high-cost drugs. Pretax margin ~1.5%.
  - **Marketplace**: Full-year MCR of 85%, including 200bps from ConnectiCare and prior-year reconciliations. Normalized MCR of 83%, with 86% expected in H2. Pretax margin ~1%.
- **Balance Sheet**: Parent company cash of $100M, debt at 1.9x EBITDA. Days in claims payable (DCP) normalized to mid-40s.
- **G&A Efficiency**: Q2 ratio of 6.1%, guiding to 6.6% for 2025. Incentive comp reduction offsets trend-driven margin pressure.

**【Q&A Highlights】**
- **Medicaid MCR Outlook**: H2 MCR expected to increase to 91% vs. H1 90.8%, driven by trend outpacing rates. States showing willingness for off-cycle rate adjustments, but not included in guidance.
- **Marketplace Strategy**: 10% of revenue, targeting mid-single-digit margins. 2026 rate filings include 11% trend assumption, acuity shift from subsidy expiration, and program integrity policies.
- **Capital Deployment**: Prioritize organic growth, then M&A (small, single-state players). Share buybacks considered after M&A pipeline activity.
- **Embedded Earnings**: $8.65 unchanged, $1 from reversing implementation costs. 1/3 of balance ($2.25) expected to materialize in 2026, dependent on rate cycle.


Molina Healthcare, Inc. (MOH) Q2 2025 Earnings Call Transcript

- **Q1 Strong Performance**: $6.08 EPS, 89.2% MCR, and $10.6B premium revenue reflect disciplined cost management. 
- **Growth Momentum**: $800M Illinois D-SNP win adds $0.50 to embedded earnings, pushing 2026 target to $46B+ premium. 
- **Marketplace Challenges**: 400bps MCR drag from one-time items, but normalized 77.7% MCR shows underlying strength. 
- **Rate Environment**: States need 200-300bps rate increases; Molina could return to 89% MCR if rates adjust. 
- **Share Buybacks**: $500M repurchased in Q1, supporting long-term 13-15% EPS growth. 


**【CEO Key Highlights】**
- **Q1 2025 Financials**: Adjusted EPS of $6.08 on $10.6B premium revenue. Consolidated MCR of 89.2%, driven by strong medical cost management and rate improvements. Medicaid MCR at 90.3%, Medicare at 88.3%, and Marketplace at 81.7% (higher due to one-time items). 
- **Growth Initiatives**: Won Illinois D-SNP contract ($800M annual premium) and defended Nevada Medicaid. Embedded earnings increased to $8.65/share (from $7.75), with $0.50 from Illinois win. 
- **2025 Guidance**: Reaffirmed $42B premium and $24.50+ EPS. Medicaid rates slightly higher than expected (+50bps), offset by trend conservatism. Marketplace MCR guidance raised to 80% (from 79%). 
- **Political Risks**: Believes Medicaid changes will be marginal. States need 200-300bps rate increases to balance programs; Molina could return to 89% MCR if rates adjust. 

**【CFO Financial Details】**
- **Q1 Results**: $11B total revenue, $10.6B premium. G&A ratio 6.8%, down 20bps YoY. Operating cash flow $190M, share buybacks $500M (1.7M shares). 
- **Balance Sheet**: Parent cash $190M, debt 2x EBITDA. Days in claims payable 46% (lower due to payment timing). 
- **2025 Guidance Updates**: Full-year MCR 88.8% (unchanged). Medicaid MCR 89.9%, Medicare 89%, Marketplace 80%. G&A ratio 6.9% (better than prior 7.0%). 
- **Embedded Earnings**: $8.65/share (up $0.90), with $2.85/share expected in 2026. 

**【Q&A Key Themes】**
- **Marketplace Volatility**: 400bps MCR drag from risk adj. true-ups and ConnectiCare acquisition. Normalized MCR 77.7%; targeting mid-single-digit margins. 
- **Cost Trends**: Medicaid rates +5% vs. prior +4.5%, offset by trend conservatism. 85% of 2025 rates already known. 
- **M&A Pipeline**: Active with $52B 2027 target. States may open RFPs to more plans due to integration needs. 
- **Legislative Impact**: Unlikely to disrupt earnings; CMS finalizing 2026 rate updates with states. 
- **Virginia Contract Loss**: $0.40 EPS headwind from mid-year termination. 


Molina Healthcare (MOH)-24 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 2024 full year +19% to $38.6B; 2025 guidance $42B (+9%).
- **EPS Outlook**: 2025 EPS ≥$24.50 (+8% YoY), driven by Medicaid rate/trend alignment and Marketplace expansion.
- **Key Metrics**: 2025 Medicaid MCR 89.9% (100bps above target), Medicare MCR 89.0%, Marketplace MCR 79.0%.
- **Growth Drivers**: $7.75 embedded earnings for 2026+ from new contracts (Georgia, duals) and acquisitions (ConnectiCare).
- **Risks**: Medicaid trend pressure (2024: 6.5% vs. 2025: 4.5%), Medicare LTSS costs, and political uncertainty.

**【CEO Summary Section】**
- **Q4 2024 Performance**: Adjusted EPS of $5.05 on $10 billion premium revenue. Full year 2024 EPS of $22.65 (+8.5% YoY), premium revenue $38.6 billion (+19% YoY). Medicaid MCR 90.3%, Medicare 89.1%, Marketplace 75.4%.
- **2025 Guidance**: $42 billion premium revenue, EPS ≥$24.50 (+8% YoY). Medicaid MCR 89.9%, Medicare 89.0%, Marketplace 79.0%. Embedded earnings increased to $7.75 for 2026+.
- **Growth Initiatives**: Acquired ConnectiCare ($1.2B revenue), won Georgia Medicaid ($2B+), and expanded duals in 4 states (+$3B revenue). 2026 target: $46B premium; 2027: $52B.

**【CFO Financial Commentary】**
- **Q4 2024 Details**: GAAP net income $420M, non-GAAP EPS $5.05. G&A ratio 6.7% (6.3% Q4). Operating cash flow $644M (impacted by risk corridor payments).
- **2025 Financials**: EPS guidance includes $1 in contract implementation costs. Medicaid rates +4.5%, trend +4.5%. Medicare MCR 89.0% due to LTSS/medication costs. Marketplace MCR 79.0% vs. 75.4% in 2024.
- **Balance Sheet**: Parent company cash $445M post-ConnectiCare acquisition. Debt 1.7x EBITDA, share buybacks $500M in Q4.

**【Q&A Key Takeaways】**
- **Medicaid Trend**: 2024 full year trend 6.5% (3.25% core utilization). 2025 assumes 4.5% trend vs. 4.5% rate increases. Q4 2024 trend 1.2% vs. expected 0.5%.
- **Medicare Pressures**: LTSS, pharmacy costs, and Bright business drag. 2025 MCR 89.0% reflects conservative bids.
- **Marketplace Growth**: 60% YoY growth (50% organic). 2025 MCR 79.0% vs. 75.4% in 2024 due to reinvested margins.
- **Political Risks**: Minimal Medicaid cuts expected; states prioritize enrollment over funding cuts.
- **Embedded Earnings**: $7.75 for 2026+ from new contracts and acquisitions, supporting 13-15% long-term EPS growth.

Actual											3.02	4.79	3.36	-0.51	4.44	3.4	2.83	2.88	4.9	4.55	4.36	4.1	5.81	5.65	5.05	4.38	5.73	5.86	6.01	5.05	6.08	5.48	1.84	-2.75
Forecast											2.9682	4.9122	2.1969	0.9556	3.6738	3.3886	2.8008	2.7488	4.659	4.3315	4.2166	4.0166	5.193	5.0987	4.8802	4.3441	5.6848	5.5636	5.8051	5.7477	5.9687	5.6183	3.9041	0.3356	2.3775
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+1.75%	-2.49%	+52.94%	-153.37%	+20.86%	+0.34%	+1.04%	+4.77%	+5.17%	+5.04%	+3.40%	+2.08%	+11.88%	+10.81%	+3.48%	+0.83%	+0.80%	+5.33%	+3.53%	-12.14%	+1.86%	-2.46%	-52.87%	-919.43%	0.00%

MOH

MOH fundamentals

MOH Q1 2026 Earnings Preview

Earnings Call

You can ask Aime

MOH

MOH fundamentals

MOH Q1 2026 Earnings Preview

Earnings Call

MOH Earnings Call Summary for Q1/2026Upcoming8:00 AM on Apr 23, 2026

MOH Earnings Call Summary for Q4/20258:00 AM on Feb 6, 2026

MOH Earnings Call Summary for Q3/20258:00 AM on Oct 23, 2025

MOH Earnings Call Summary for Q2/20258:00 AM on Jul 24, 2025

MOH Earnings Call Summary for Q1/20258:00 AM on Apr 24, 2025

You can ask Aime